Literature DB >> 32822318

A retrospective analysis of congenital anomalies in congenital hypothyroidism.

Fatima Ali Mazahir1, Manal Mustafa Khadora2.   

Abstract

Objectives We evaluated the spectrum of diseases accompanying congenital hypothyroidism (CH) in the United Arab Emirates and compared them with internationally studied patterns. Methods The presented retrospective cross-sectional study took place in two government tertiary care centres. In total, 204 patients with a confirmed diagnosis of CH and a minimum period of follow-up of 1 year were included. Patients with Down syndrome, infants born at <35 weeks of gestation, and babies with TORCH (Toxoplasma gondii, Other viruses [HIV, measles, etc.], Rubella, Cytomegalovirus, and Herpes simplex) infections were subsequently excluded from the study. Results Of the subjects with CH, 39% had associated extrathyroidal anomalies (ETAs); among these, 25% had a single anomaly. A significant proportion of Arab males were affected by CH as compared to other ethnic groups. Dyshormonogenesis was the commonest aetiological cause (55%) of CH. Males with an ectopic lingual thyroid gland had significant ETAs as compared to females of the same cohort. The most common ETAs were congenital heart disease (16%), followed by urogenital tract anomalies (14%). Conclusions Detection of a high rate and variability of ETAs associated with CH necessitates the formulation of a structured screening programme including appropriate clinical, laboratory, and imaging tools to detect ETAs at an earlier stage.

Entities:  

Keywords:  anomalies; congenital hypothyroidism; endocrinology; neonatal screening; paediatrics

Mesh:

Substances:

Year:  2020        PMID: 32822318     DOI: 10.1515/jpem-2020-0250

Source DB:  PubMed          Journal:  J Pediatr Endocrinol Metab        ISSN: 0334-018X            Impact factor:   1.634


  1 in total

1.  Serological Characteristics, Etiological Analysis, and Treatment Prognosis of Children with Congenital Hypothyroidism.

Authors:  Lin Shen; Jingchao Ding
Journal:  Emerg Med Int       Date:  2022-09-27       Impact factor: 1.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.